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Abstract
The treatment of oral and periodontal diseases and associated anomalies accounts for a significant proportion of 
the healthcare burden, with the manifestations of these conditions being functionally and psychologically debili-
tating. A challenge faced by periodontal therapy is the predictable regeneration of periodontal tissues lost as a 
consequence of disease. Growth factors are critical to the development, maturation, maintenance and repair of 
oral tissues as they establish an extra-cellular environment that is conducive to cell and tissue growth. Tissue en-
gineering principles aim to exploit these properties in the development of biomimetic materials that can provide 
an appropriate microenvironment for tissue development. The aim of this paper is to review emerging periodontal 
therapies in the areas of materials science, growth factor biology and cell/gene therapy. Various such materials 
have been formulated into devices that can be used as vehicles for delivery of cells, growth factors and DNA. Dif-
ferent mechanisms of drug delivery are addressed in the context of novel approaches to reconstruct and engineer 
oral and tooth supporting structure.
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Concept
National Institute of Health defines tissue engineering 
as, an emerging multidisciplinary field in-volving biol-
ogy, medicine, and engineering that is likely to revo-
lutionize and improve the health and quality of life for 
millions of people worldwide by restoring, maintaining, 
or enhancing tissue and organ function. Periodontal tis-
sue engineering deals with the repair of alveolar bone, 
tooth-associated cementum and periodontal ligament 
(PDL).
Dental tissue engineering is a relatively new field of 
reconstructive biology which utilizes mechani-cal, cel-
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lular or biologic mediators to facilitate regeneration of 
a particular tissue. It is now being successfully used 
for human application. This review article focuses on 
the emerging concepts and results of the application of 
biomaterials, growth factors and cell/gene therapy on 
the proteins, genes and cells to regenerate the lost peri-
odontium. 
Periodontal regeneration 
Periodontal regeneration is defined as reproduction or 
reconstruction of a lost or injured part so that form and 
function of lost structures are restored. The regeneration 
of the periodontal tissues is de-pendent on four basic 
components. The appropriate signals, cells, blood sup-
ply and scaffold needed to target the tissue at the defect 
site (Fig 1) (1). All these elements play a fundamental 
role in the healing process and in the reconstruction of 
the lost tissue. The cells provide the machinery for new 
tissue growth and differentiation where as the growth 
factors or morphogens modulate the cellular activity 
and provide stimuli to the cells to differentiate and pro-
duce matrix for the developing tissue The new vascular 
networks provide the nutritional base for tissue growth 
and homeostasis. Finally, scaffolds guide and create a 
template structure three-dimensionally to facilitate the 
above processes required for tissue regeneration.
Role of growth factors in periodontal tissue enginee-
ring
Growth factors are proteins that may act locally or sys-
temically to affect the growth and function of cells in 
several ways.  The application of growth factors to re-
store damaged tissues aims at regeneration through bio-
mimetic processes, or mimicking the processes that oc-
cur during em-bryonic and post-natal development. The 
effects of growth factors in different phases of wound 
healing have been illustrated in (Table 1) (2).  
Platelet- derived growth factor (PDGF) was the first 
growth factor to be evaluated in preclinical periodon-
tal and peri-implant regenerative studies. Proliferation, 
migration and matrix synthesis were observed on cul-
tures of periodontal cells stimulated by PDGF, includ-
ing gingival and PDL fi-broblasts, cementoblasts,  pre 
osteoblasts and osteoblastic cells. The PDGF family 
is composed of four growth factors: PDGF-A, -B, and 
the most recently discovered  are PDGF-C and –D.  All 
of these participate in the wound-healing process, but, 
until now, only the three isoforms PDGF-AA, BB and 
AB were evaluated in periodontal therapy.  PDGF-BB 
is most effective on PDL cell mito-genesis and matrix 
biosynthesis (3).
According to Howell et al. (4),  in a human Phase I/
II clinical trial, PDGF/Insulin Growth Factor -I were 
considered safe when applied topically to periodontal 
osseous lesions, resulting in a significant improvement 
in bone growth and fill of periodontal defects, compared 
with standard therapy. According to Park et al. (5) and 
Cho et al. (6), PDGF alone was demonstrated in two 
preclinical studies in dogs in which alveolar bone de-
fects of critical size were completely regenerated after 
treatment with PDGF-BB associated to guided tissue 
regeneration (GTR). The results were superior to the 
same treatment without PDGF. The authors concluded 
that PDGF stimulated formation of fibrous connective 
tissue in an early stage of repair, filling and stabilizing 
the wound. In a subse-quent regenerative stage, the fi-
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Fig. 1. The Four Critical Elements Required In Periodontal Tissue Engineering.
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brous tissue was substituted with new bone and PDL.          
Wang et al. (7) showed enhanced fibroblast prolifera-
tion in early periodontal wound healing, after treatment 
of alveolar bone defects in dogs with PDGF.  Camelo 
et al. (8) and Nevins et al. (9) conducted two studies 
using PDGF-BB with demineralised freeze-dried bone 
allograft in the treat-ment of different types of critical 
size periodontal bone defects. Histological sections pro-
vided evi-dence of periodontal regeneration.
Jayakumar et al. (10) conducted a multi-centre clinical 
trial on 54 patients with periodontal osse-ous defects. 
The patients were randomly assigned to rhPDGF-BB+β-
TCP or β-TCP. Following periodontal surgery, respec-
tive implantation was performed. The primary and sec-
ondary end points of treatment were evaluated at the 
third and the sixth month. They reported a significant 
increase in the extent of linear bone growth and per cent 
bone fill over baseline in the rhPDGF-BB+β-TCP group 
when compared with the β-TCP group. Similarly, it also 
resulted in significantly higher area under the curve 
clinical attachment level gain at 0-6 months (p<0.01), 
CAL gain and greater reduc-tion in probing depth at the 
 
WOUND-HEALING 
PHASE 
GROWTH
FACTOR
CELL OF ORIGIN FUNCTIONS 
INFLAMMATORY PDGF Platelets Increases chemotaxis of neutrophils and monocytes. 
 
TGF-ȕ 
Platelets, leukocytes, 
fibroblasts 
Increases chemotaxis of neutrophils and monocytes. 
Autocrine expression generation of additional cytokines(TNF-
alpha, IL-1beta, PDGF and chemokines) 
 
VEGF 
Platelets, leukocytes, 
fibroblasts 
Increase vascular permeability. 
PROLIFERATIVE EGF 
Macrophages, 
mesenchymal cells, 
platelets 
Stimulates epithelial proliferation and migration. 
 
FGF-2 
Macrophages, endothelial 
cells 
Stimulates fibroblasts proliferation and ECM synthesis. 
Increase chemotaxis, proliferation and differentiation of 
endothelial cells. 
 KGF(FGF-7) Keratinocytes, fibroblasts Stimulates epithelial proliferation and migration. 
 
PDGF 
Macrophages, endothelial 
cells 
Stimulates fibroblasts proliferation and ECM synthesis. 
Increase chemotaxis, proliferation and differentiation of 
endothelial cells. 
 
TGF-beta 
Macrophages, leukocytes, 
fibroblasts 
Stimulates epithelial proliferation and migration. 
Stimulates fibroblasts proliferation and ECM synthesis. 
Inhibits proteases and enhances inhibitor production. 
 
VEGF Macrophages 
Increases chemotaxis of endothelial progenitor cells. 
Stimulates endothelial cell proliferation 
BONE REMODELLING 
AND MATRIX 
SYNTHESIS 
BMPs 2-4 Osteoblasts Stimulates mesenchymal progenitor cell migration 
 BMP-7 Osteoblasts Stimulates osteoblast and chondroblast differentiation. 
 
FGF-2 
Macrophages, endothelial 
cells 
Stimulates mesenchymal progenitor cell migration. 
 IGF-2 Macrophages, fibroblasts Stimulates osteoblast proliferation and bone matrix synthesis. 
 
PDGF Macrophages 
Stimulates differentiation of fibroblasts into myofibroblasts. 
Stimulates proliferation of mesenchymal progenitor cells. 
 
TGF-ȕ Fibroblasts, osteoblasts 
Induces endothelial cell and fibroblast apoptosis. 
Induces differentiation of fibroblasts into myofibroblasts. 
Stimulates chemotaxis and survival of osteoblasts 
 
VEGF Macrophages 
Chemotaxis of mesenchymal stem cells, antiapoptotic effect 
on the bone-forming cells, angiogenesis promotion. 
BMP: Bone morphgenetic protein; ECM: Extracellular matrix; EGF: Epidermal growth factor; FGF: Fibroblast growth factor; IGF: Insulin-like 
growth factor; KGF: Keratinocyte growth factor; PDGF: Platelet derived growth factor; TGF: Transforming growth factor; VEGF: Vascular 
endothelial growth factor. (From Kaigler D, Cirelli JA, Giannobile WV. Expert Opin Drug Deliv. 2006; 3: 647-62.) 
Table 1.  Effects of growth factors in the different phases of wound healing.
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third and the sixth month than that with β-TCP treat-
ment alone. 
According to Takayama et al. (11) and Terranova et al. 
(12) the angiogenic and fibroblast stimula-tory proper-
ties of Fibroblast growth factor (FGF-2) during wound 
healing and its chemotactic and proliferative effects on 
PDL cells, suggest its use for periodontal regenerative 
therapeutic ap-proaches. Many preclinical studies were 
conducted using this growth factor. Despite different 
con-centrations of FGF-2 and different delivery systems 
used in these studies, all showed an improve-ment in the 
periodontal tissue regeneration, compared with control 
groups. These studies also sug-gested that its effects are 
dose dependent (13). 
Kitamura et al. (14) investigated the efficacy of the local 
application of recombinant human fibro-blast growth fac-
tor-2 (FGF-2) in periodontal regeneration by conducting 
a double-blind, placebo-controlled clinical trial in 253 
adult patients with periodontitis. Modified Widman peri-
odontal sur-gery was performed, during which 200 μL 
of the investigational formulation containing 0% (vehicle 
alone), 0.2%, 0.3%, or 0.4% FGF-2 was administered to 
2-or 3-walled vertical bone defects. Each dose of FGF-2 
showed significant superiority over vehicle alone for the 
percentage of bone fill at 36 wks after administration, and 
the percentage peaked in the 0.3% FGF-2 group. They 
hence concluded that topical application of FGF-2 can be 
efficacious in the regeneration of human perio-dontal tis-
sue that has been destroyed by periodontitis. 
Transforming growth factor –β (TGF- β) is a multi-
functional growth factor structurally related to bone 
morphogenetic protein but is functionally quite differ-
ent. However, TGF-β can control gene expression either 
positively or negatively, a factor that can interfere with 
its therapeutic use (15). TGF-β1, the most abundant iso-
form of the TGF-β family and found primarily in the 
platelets and osseous tissue, has been used for this ap-
plication. Clokie et al. suggested that TGF-β1 increased 
the amount of bone healing adjacent to dental implants 
in mini pigs (15). TGF-β1 seems to play an im-portant 
role in inducing fibroblastic differentiation of PDL stem/
progenitor cells and in maintaining the PDL apparatus 
under physiological conditions (16).
Markopoulou et al. (17) evaluated the in vitro effect of 
recombinant human transforming growth factor-beta 
1 (rhTGF-β1) combined with two different bone grafts 
on human PDL (hPDL) cell dif-ferentiation. The hPDL 
cells were treated with TGF-β1 alone or in combination 
with a calcified freeze-dried bone allograft (FDBA) and 
a porous biphasic calcium phosphate (BC) bone graft. 
Cell differentiation effect was estimated by measur-
ing alkaline phosphatase (ALPase) activity and os-te-
ocalcin secretion. Results demonstrated that rhTGF-β1 
alone or in combination with FDBA and BC provoked 
a significant increase in ALPase activity as compared 
with controls. The findings of this study confirmed the 
beneficial role of rhTGF-β1 combined with FDBA and 
BC as carriers in periodontal regeneration.
Another important group of proteins for therapeutic ap-
plications are the Bone morphogenetic proteins (BMP). 
BMPs -2,-4, -7 and -12 have all been evaluated for peri-
odontal and peri-implant bone regeneration. BMP-2 
has been the most studied for bone and periodontal re-
generative treat-ment (18). Several preclinical studies 
demonstrate significant improvement of alveolar bone 
regen-eration in different types of periodontal defects 
after treatment with rh BMP-2 via different carriers.
Another important therapeutic application of BMPs is 
for maxillary bone regeneration to allow replacement of 
lost teeth by osseointegrated dental implants. This ap-
proach involves the re-generation of peri-implant bone 
after implant fixation or bone height improvement in ar-
eas below the maxillary sinus. Preclinical (19) and clini-
cal (20) studies have shown improved bone formation 
after treatment with BMP-2. However, the use of dif-
ferent carriers and the association of barrier membrane 
(GTR technique) or other biomaterials seem to be criti-
cal factors in influencing the therapeutic outcome.
BMP-7 or osteogenic protein-1 is a potent modulator 
of osteogenesis and bone cell differentiation. Its effect 
in periodontal-regenerative treatment was evaluated in 
bony defects around tooth roots in preclinical studies. 
Significant improvement on bone and cementum regen-
eration was observed in dogs (21). An extensive cemen-
togenesis was considered the most significant effect of 
BMP-7 in bony defects in baboons (22). Improvement 
of bone formation around titanium implants was also 
demonstrated by studies in animals (23).
The potential of BMP-12 to repair tendon and PDL tis-
sues has been shown in vitro and in vivo stud-ies (24). 
A preliminary study in dogs compared rhBMP-12 with 
rhBMP-2 for the treatment of periodontal defects. The 
results showed less bone and more functionally oriented 
PDL between the new bone and new cementum after 
BMP-12 treatment, contrasting with a more parallel 
fiber ar-rangement of BMP-2-treated defects (25).
Moore YR, Dickinson DP, Wikesjo UM (26)   con-
ducted a comprehensive literature search to re-view the 
therapeutic effects of Growth/differentiation factor-5 
(GDF-5), a member of the bone morphogenetic pro-
tein family. They concluded that GDF-5 appears to be 
a promising therapeutic agent for periodontal wound 
healing/regeneration as it supports/accelerates bone and 
ten-don/ligament formation in several musculoskeletal 
settings including periodontal tissues.
Kwon et al. (27) clinically evaluated the injectability, 
biocompatibility, safety, and periodontal wound heal-
ing/regeneration following application of a novel biore-
sorbable recombinant human growth/differentiation fac-
tor-5 (rhGDF-5)/ poly (lactic-co-glycolic acid) (PLGA) 
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construct. Bone formation showed apparent increased 
maturity (lamellar bone) at 6 weeks in sites receiving 
rhGDF-5/PLGA compared with the control. Both proto-
cols exhibited significant increases in PDL, cemen-tum, 
and bone regeneration over time. Increased bone for-
mation was observed at sites receiving rhGDF-5/PLGA. 
They concluded that the rhGDF-5/PLGA construct ap-
pears to be a safe technol-ogy for injectable, ease-of-use 
application of rhGDF-5-stimulated periodontal wound 
heal-ing/regeneration. However, additional work to op-
timize the polymer carrier and rhGDF-5 release kinet-
ics/dose might be required before evaluating the efficacy 
of this technology in clinical settings using minimally 
invasive approaches.
Though the results from preclinical and initial clini-
cal studies using growth factors are encouraging, some 
limitations exist with respect to bone volume and pre-
dictability. Although in vitro studies have elucidated 
the role of growth factors in the cellular events of the 
different type of cells, several factors may influence 
the results in vivo. Limitations that restrict optimal re-
sponses of growth factor delivery include the short half-
life of growth factors after being delivered in vivo. This 
may be due to proteolytic degradation, rapid diffusion 
and the solubility of delivery vehicles in chronic perio-
dontal wounds. 
Amelogenins are a family of extracellular matrix 
proteins that regulate the initiation and growth of hy-
droxyappatite crystals during mineralization of the 
enamel. An acidic extract of enamel matrix derivative 
is being evaluated for clinical use. Enamel matrix de-
rivative (EMD), uses proteins that are derived from em-
bryonic enamel matrix with the purpose of mimicking 
the specific events that occur during the development 
of the periodontal tissues. EMD uses propylene glycol 
alginate as a vehicle in a viscous formulation. After 
coating the tooth root close to the periodontal defect, 
the propylene glycol alginate viscosity is reduced under 
physiological conditions and facilitates EMD release 
and precipitation.    
Trombelli et al. (28)  reviewed clinical effects of the use 
of recombinant human platelet-derived growth factor-
BB (rhPDGF-BB), platelet-rich plasma (PRP), commer-
cially available enamel matrix derivative (cEMD) and 
peptide P-15 (P-15) (BAs) for the treatment of intra-
osseous and furcation defects when used in addition to 
open flap debridement either alone or in association with 
guided tissue regeneration (GTR). They concluded that: 
(1) cEMD either alone or in combination with grafts can 
be effectively used to treat intra-osseous defects and 
the clinical results appear to be stable long term; (2) the 
additional use of a graft seems to enhance the clinical 
outcome of cEMD; (3) the combined use of rhPDGF-BB 
and P-15 with a graft biomaterial has beneficial effects 
in intra-osseous defects.
Esposito et al. (29) conducted a systematic review to test 
whether EMD is effective, and to com-pare EMD ver-
sus GTR, and various bone grafting procedures for the 
treatment of intrabony defects. They reported that after 
one year of application of EMD, there was significant 
improve-ment in the probing attachment levels (1.1 mm) 
and reduced pocket depths (0.9 mm) when compared to 
a placebo or control, however, the high degree of hetero-
geneity observed among trials suggested that the results 
have to be interpreted with great caution. In addition, a 
sensitivity analy-sis indicated that the overall treatment 
effect might be overestimated. The actual clinical ad-
vantages of using EMD are unknown. With the excep-
tion of significantly more postoperative complications 
in the GTR group, there was no evidence of clinically 
important differences between GTR and EMD. Bone 
substitutes may be associated with less gingival reces-
sion than EMD. 
Growth factor delivery for periodontal tissue enginee-
ring
The concepts of GTR and guided bone regeneration 
have been used to retard apical migration of epithelial 
cells favoring the healing by cells from the PDL region 
and adjacent alveolar bone. Thus, different membranes 
are used in these procedures as barriers. The develop-
ment of both naturally de-rived and synthetic materials 
allows the degradation properties to be controlled by the 
composition and ratios of compounds that comprise the 
material. The advantage is that, with the more recently 
devel-oped polymers, these properties can be tailored to 
meet the specific needs of the application as to how long 
one desires to have the material maintained.
The tissue-engineering strategies involve the use of dif-
ferent polymer systems to serve as synthetic extracel-
lular matrices. These polymers serve as delivery depots 
not only for growth factors and DNA molecules, but 
also for cells.  Cells can be delivered after ex vivo ex-
pansion and combined with bioma-terials to continually 
proliferate and differentiate into new tissues. Success-
ful regeneration and engi-neering of a wide variety of 
oral structures have been demonstrated with this cell 
transplantation ap-proach, and these tissues include 
bone, PDL, oral mucosa, skin and teeth. Cells can also 
be genetically modified ex vivo prior to implantation, 
creating a combined gene therapy–cell transplantation 
approach. 
Two common types of polymeric materials used in 
growth factor delivery strategies are natural colla-gen-
derived materials and synthetic polymers of lactic and 
glycolic acid (i.e., poly (lactide-co-glycolide)). Extracel-
lular matrix-derived macromolecules such as collagen 
have been used for many years in biomaterial applica-
tion, and it is now possible to create artificial analogues 
of extracellular matrix proteins using recombinant 
DNA technology. Collagen is degraded by cells within 
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regenerating tissue, and biodegradable synthetic poly-
mers such as poly (lactide-co-glycolide) are hydrolysed 
into natural metabolites, lactic acid and glycolic acid by 
the action of water at regenerated sites. The poly (lac-
tide-co-glycolide) scaffolds are popularly employed due 
to familiarity with their functional proper-ties and uses 
in other applications (e.g., biodegradable sutures). Ad-
ditionally, growth factors and DNA can be incorporated 
into these materials and released in a controlled, sus-
tained ma nner to enhance tissue regeneration. 
A variety of new injectable materials such as hydrogels 
are also being developed for growth factor delivery ap-
plications. These injectables are especially attractive 
because, in clinical application, they can allow for mini-
mally invasive delivery of inductive molecules. As an 
example, alginate hydrogels bearing cell-adhesion lig-
ands have been used as scaffolds for cell encapsulation 
and transplantation, and have yielded promising results 
in experiments directed toward the engineering of bone 
tissue (7). Another group of polymers are the biomimet-
ic polymers. These polymers combine the information 
content and multifunctional character of natural mate-
rials with the mechanical properties of synthetic poly-
mers. This hybrid concept has been used in the binding 
of polymers with specific amino acids (such as the tri-
peptide sequence RGD) that are capable of regulating 
cell adhesion. 
Another area of increasing attention has been the de-
velopment of shape-memory materials that have one 
shape at one temperature and another shape at a dif-
ferent temperature. These materials have the ability to 
memorize a permanent shape that can be substantially 
different from an initial temporary shape. As an exam-
ple, a bulky device could potentially be introduced into 
a surgical site as a temporary shape (such as a string or 
freely flowing material), penetrate through a small area 
of the site, and then be expanded in response to different 
cues into a permanent shape (i.e., a stent or a sheet). The 
response signals that stimulate the changes in shape in 
response to environmental cues are incorporated within 
the material during its fabrication. These materials have 
been designated as ‘smart’ materials, having the ability 
to appropriately change their structural and functional 
material properties in response to environmental cues. 
These materials have also demonstrated great promise 
and the ability to control their built-in signaling is what 
makes them attractive for growth factor delivery strate-
gies (30).  
Gene therapy for periodontal tissue regeneration
Gene therapy may achieve greater bioavailability of 
growth factors within periodontal wounds, which may 
provide greater regenerative potential. Gene therapy in-
volves the transfer of genetic information to target cells, 
which enables them to synthesize a protein of interest to 
treat a disease. The preferred strategy for gene transfer 
depends on the required duration of protein release and 
the morphology of the target site.
Gene transfer is accomplished through the use of viral 
and nonviral vectors. Examples of viral vec-tors are ret-
roviruses, adenoviruses (Ad) and adeno-associated vi-
ruses (AAV), and nonviral vectors include plasmids and 
DNA polymer complexes.  Retroviruses introduce RNA 
together with two enzymes, called reverse transcriptase 
and integrase, into the target cell. Initially, the reverse 
tran-scriptase enables the production of a DNA copy 
from the retrovirus RNA molecule. Subsequently, the 
integrase adds the DNA copy into the target cell DNA. 
When the genetically altered host cell divides later, its 
descendants contain the modified DNA. Because the 
integrase enzyme may insert the DNA copy into an ar-
bitrary position of the target cell DNA, gene disruption 
and uncontrolled cell division (that is, cancer) may oc-
cur (1).  
Ad contains DNA, which is introduced into the target 
cell and subsequently transferred into its nucleus. In 
contrast to the fate of the retrovirus DNA copy, the Ad-
DNA is not incorporated into the host cell’s genetic ma-
terial. Consequently, when the Ad-infected target cell 
divides later, its descendants are not genetically altered, 
nor do they contain the Ad-DNA genetic material. AAV 
derived from parvovirus family, are small viruses with 
a single-stranded DNA genome that causes no known 
human diseases. The AAV infects dividing and non di-
viding cells by integrating its ge-netic material on chro-
mosomes of the target cell. Types of recombinant AAV 
have been developed either to remain extra chromo-
somal or integrate into nonspecific chromosomal sites. 
Research has demonstrated that the AAV can be used to 
correct genetic defects in animals. One disadvantage of 
the AAV is that it is small and possesses the capacity to 
carry no more than usually two genes. 
Nonviral alternatives do not have the drawbacks of un-
desired host immune reactions or potential tumorigen-
esis so they likely would be given more consideration in 
the future. Plasmids and DNA polymer complexes carry 
the genetic information in the form of DNA to express 
a foreign protein. Various design features of nonviral 
delivery of DNA include chromosomal integration and 
their ability to alter gene expression. 
Various gene delivery methods are available to admin-
ister growth factors to periodontal defects for tissue 
engineering (Fig 2) (2).   The delivery method can be 
tailored to the specific characteristics of the wound site. 
For example, a horizontal one- or two-walled defect 
may require the use of a sup-portive carrier, such as a 
scaffold where as other defect sites may be conducive to 
the use of an Ad vector embedded in a collagen matrix. 
The most important point is the risk associated with the 
use of gene therapy in periodontal tissue engineering. 
Studies that examine the use of specific delivery meth-
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ods and DNA vectors in periodontal tissue engineering 
reflect the aim to maximize the dura-tion of growth fac-
tor expression, optimize delivery method to periodontal 
defect, and minimize patient risk.
Complementary Explorations
Preclinical studies that evaluate growth factor gene 
therapy for tissue engineering
To overcome the short half-lives of growth factor pep-
tides in vivo, gene therapy that uses a vector that encodes 
the growth factor is utilized to stimulate tissue regen-
eration. The two main strategies of gene vector deliv-
ery have been applied to periodontal tissue engineering. 
Gene vectors can be introduced directly to the target site 
(in vivo technique) (31) or selected cells can be harvested, 
ex-panded, genetically transduced, and then reimplanted 
(ex vivo technique). In vivo gene transfer involves the in-
sertion of the gene of interest directly into the body an-
ticipating the genetic modification of the target cell. Ex 
vivo gene transfer includes the incorporation of genetic 
material into cells exposed from a tissue biopsy with sub-
sequent reimplantation into the recipient. 
Platelet-derived growth factor gene delivery
The PDGF-gene transfer strategies have been used in 
tissue engineering to improve healing in soft tissue 
wounds, such as skin lesions. 
Chen et al. (32) were able to demonstrate the prolonged 
effects of Ad delivery of PDGF for the better under-
standing of sustained PDGF signaling. Ad encoding 
PDGF-β transduced gingival fibroblasts and enhanced 
defect fill by induction of human gingival fibroblast mi-
gration and proliferation. On the other hand, continuous 
exposure of cementoblasts to PDGF-α had an inhibitory 
effect on cementum mineralization, possibly via the up-
regulation of osteopontin and subsequent enhancement 
of multinucleated giant cells in cementum-engineered 
scaffolds. Ad/PDGF-1308 (a dominant-negative mutant 
of PDGF) inhibited mineralization of tissue-engineered 
cementum possibly because of downregulation of bone 
sialoprotein and osteocalcin with a persistence of stimu-
lation of multinucleated giant cells. These findings sug-
gested that continuous exogenous delivery of PDGF-α 
may delay mineral formation induced by cementoblasts, 
whereas PDGF clearly is required for mineral neogenesis .
Jin et al. (31) demonstrated that direct in vivo gene 
transfer of PDGF-B stimulated tissue regenera-tion in 
large periodontal defects. Descriptive histology and 
histomorphometry revealed that human PDGF-B gene 
delivery promotes the regeneration of cementum and al-
veolar bone, whereas PDGF-1308, a dominant-negative 
mutant of PDGF-A, has minimal effects on periodontal 
tissue regenera-tion.
Fig. 2. Gene therapy approaches A. DNA and growth factors can be delivered to cells through different mechanisms, including direct injection 
to an in vivo site, transport to a site via a carrier matrix, or introduced ex vivo prior to cell transplantation. B. Genetic material can be transferred 
into cells using different vectors, the most common of which are plasmids, retroviruses, adenoviruses and adeno- associated viruses. C. Growth 
factor delivery by gene therapy strategies aim to modulate cell proliferation, migration, matrix synthesis and differentiation. (From Kaigler D, 
Cirelli JA, Giannobile WV. Expert Opin Drug Deliv. 2006; 3: 647-62.)
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Bone Morphogenetic protein gene delivery
Lieberman et al. (33) demonstrated gene therapy for 
bone regeneration, they transduced the bone marrow 
stromal cells with rhBMP-2 to form bone within an ex-
perimental defect comparable to skeletal bone. Baltzer 
et al. (34) showed regeneration of skeletal bone by di-
rectly administering Ad5/BMP-2 into a bony segmental 
defect in rabbits. Further advances in the area of ortho-
pedic gene therapy using viral delivery of BMP-2 have 
provided further evidence for the ability of in vivo and 
ex vivo bone engineering. Franceschi et al. (35) inves-
tigated in vitro and in vivo Ad gene trans-fer of BMP-7 
for bone formation. Ad-transduced nonosteogenic cells 
also were found to differenti-ate into bone-forming 
cells and produce BMP-7 or BMP-2 in vitro and in vivo. 
Study by Huang et al. (36) using plasmid DNA encod-
ing for BMP-4 with a scaffold delivery system was 
found to en-hance bone formation when compared with 
blank scaffolds. 
In an early approach to regenerate alveolar bone in an 
animal model, the ex vivo delivery of Ad-encoding 
murine BMP-7 was found to promote periodontal tis-
sue regeneration in large mandibular periodontal bone 
defects (37).  BMP-7 gene transfers not only enhanced 
alveolar bone repair but also stimulated cementogenesis 
and PDL fiber formation. Of interest, the alveolar bone 
formation was found to occur via a cartilage interme-
diate. When genes that encoded the BMP antagonist 
nog-gin were delivered, inhibition of periodontal tissue 
formation resulted.  A recent study by Dunn et al. (38) 
showed that direct in vivo gene delivery of Ad/BMP-7 
in a collagen gel carrier promoted successful regenera-
tion of alveolar bone defects around dental implants. 
These experiments provide promising evidence that 
shows the feasibility of in vivo and ex vivo gene therapy 
for periodontal tissue regeneration and peri-implant os-
seointegration.
Angiogenic factors for periodontal repair
The blood supply has a key role on the nutrition of new-
ly engineered tissues. However, a major chal-lenge in 
periodontal regeneration is the targeting of angiogen-
esis to an avascular tooth root surface. Basic fibroblast 
growth factor (bFGF or FGF-2) has been demonstrated 
to have potent angiogenic activity and potential to in-
duce the growth of immature PDL cells. The mRNA 
level of laminin in PDL cells, which plays an important 
role in angiogenesis, is up regulated by FGF-2 stimula-
tion. Thus it may in turn accelerate periodontal regen-
eration.
Enamel Matrix Derived protein (EMD) has angiogenic 
effects both in vitro and in vivo. The more rapid initial 
healing may not be directly influenced by the angiogen-
ic effect of EMD alone. At least two other mechanisms 
probably contribute to the acceleration of wound heal-
ing. First, PDL cells se-crete growth factors, including 
TGF-β1, IL-6, and PDGF-AB after exposure to EMD. 
TGF-β1 and PDGF-AB have been shown to accelerate 
the rate of healing in periodontal wounds by specifically 
stimulating the proliferation of PDL cells. Second, it has 
been demonstrated that EMD can modulate the bacte-
rial growth of putative periodontal pathogens (Actino-
bacillus actinomycetemcomitans, Por-phyromonas gin-
givalis, and Prevotella intermedia), but not the normal 
flora during periodontal wound healing.   
The technical challenges confronting the tissue engi-
neering of vasculature are many.  First is the selec-tion 
of appropriate vascular cells and scaffold materials. 
The majority of studies to date typically in-volve in 
vitro culturing of bone marrow cells or smooth muscle 
cells in combination with a collagen-based matrix until 
a tubular structure is formed, thus allowing endothelial 
cells to attach to the vessel wall. Scaffolds need to be 
designed to support the proper formation of vascular 
tissue and possess the mechanical properties that can 
match those of native arteries. The synthetic vessel 
must withstand the fluid shear stress and strain from 
blood flow and have adequate burst strength to with-
stand physiological blood pressures.  Finally; incompat-
ibilities between synthetic engineered grafts and native 
blood vessels must be quantified and evaluated.
Well-defined discriminating preclinical models fol-
lowed by well-designed clinical trials are needed to 
further investigate the true potential of these growth 
and differentiation factors (39).  All current or emerg-
ing paradigms have either been shown to have limited 
and variable outcomes or have yet to be developed for 
clinical use. To accelerate clinical translation, there is 
an ongoing need to develop therapeutics based on en-
dogenous regenerative technology (ERT), which can 
stimulate latent self-repair mechanisms in patients and 
harness the host’s innate capacity for regeneration. ERT 
in perio-dontics applies the patient’s own regenerative 
‘tools’, i.e. patient-derived GFs and fibrin scaffolds, 
sometimes in association with commercialized prod-
ucts (e.g. Emdogain and Bio-Oss), to create a ma-terial 
niche in an injured site where the progenitor/stem cells 
from neighboring tissues can be recruited for in situ 
periodontal regeneration (40).  
Conclusion
A review of literature on the use of growth regulatory 
molecules along with gene therapy permits a model to 
consider approaches to oral tissue engineering. Devel-
opments in polymeric and ceramic scaffolding systems 
for cell, protein and gene delivery have undergone sig-
nificant growth. The tar-geting of signaling molecules 
or growth factors (via proteins or genes) to the perio-
dontium has lead to significant new knowledge regard-
ing use of  bioactive molecules to promote cell prolifera-
tion, differentiation, matrix biosynthesis, and angiogen-
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esis. For improvements in the outcomes in perio-dontal 
regenerative medicine, scientists will need to examine 
dual delivery of host modifiers or anti-infective agents 
to optimize the results of therapy. For future growth and 
development in the field of oral tissue –engineering, 
combination of several multi disciplinary approaches 
including engineer-ing, dentistry and medicine will be 
needed.
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